Apellis to dose first patient in Phase 2 MERIDIAN study. Apellis expects to dose first patient in Phase 2 MERIDIAN study by year-end
In October 2020, Apellis announced the initiation of registrational programs of pegcetacoplan in patients with immune complex membranoproliferative glomerulonephritis or C3G and in patients with amyotrophic lateral sclerosis.
The IC-MPGN / C3G registrational program consists of the recently initiated Phase 2 NOBLE study focused on the histopathology of the kidneys and a Phase 3 study that is expected to begin in the first half of 2021. The company expects the first patient to be dosed in the potentially registrational Phase 2 MERIDIAN study in ALS, Apellis' first neurological program, by the end of 2020.